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Resveratrol Has Antiinﬂammatory and Antiﬁbrotic Effects in
the Peptidoglycan-Polysaccharide Rat Model of Crohn’s
Disease
Kinan Rahal, MD,* Phyllissa Schmiedlin-Ren, MD,* Jeremy Adler, MD, MSc,†
Muhammad Dhanani, BA,* Victoria Sultani, BA,* Ahren C. Rittershaus, MD,‡ Laura Reingold,*
Ji Zhu, PhD,§ Barbara J. McKenna, MD,‡ Gregory M. Christman, MD,¶ and Ellen M. Zimmermann, MD*
Background: Resveratrol has antiinﬂammatory and antiﬁbrotic effects. Resveratrol decreases proliferation and collagen synthesis by intestinal
smooth muscle cells. We hypothesized that resveratrol would decrease inﬂammation and ﬁbrosis in an animal model of Crohn’s disease.
Methods: Peptidoglycan-polysaccharide (PG-PS) or human serum albumin (HSA) was injected into the bowel wall of Lewis rats at laparotomy.
Resveratrol or vehicle was administered daily by gavage 1–27 days postinjection. On day 28, gross abdominal and histologic ﬁndings were
scored. Cecal collagen content was measured by colorimetric analysis of digital images of trichrome-stained sections. Cecal levels of procollagen,
cytokine, and growth factor mRNAs were determined.
Results: PG-PS-injected rats (vehicle-treated) developed more ﬁbrosis than HSA-injected rats by all measurements: gross abdominal score (P <
0.001), cecal collagen content (P ¼ 0.04), and procollagen I and III mRNAs (P  0.0007). PG-PS-injected rats treated with 40 mg/kg resveratrol
showed a trend toward decreased gross abdominal score, inﬂammatory cytokine mRNAs, and procollagen mRNAs. PG-PS-injected rats treated
with 100 mg/kg resveratrol had lower inﬂammatory cytokine mRNAs (IL-1b [3.50 6 1.08 vs. 10.79 6 1.88, P ¼ 0.005], IL-6 [17.11 6 9.22 vs.
45.64 6 8.83, P ¼ 0.03], tumor necrosis factor alpha (TNF-a) [0.80 6 0.14 vs. 1.89 6 0.22, P ¼ 0.002]), transforming growth factor beta 1
(TGF-b1) mRNA (2.24 6 0.37 vs. 4.06 6 0.58, P ¼ 0.01), and histologic ﬁbrosis score (6.4 6 1.1 vs. 9.8 6 1.0; P ¼ 0.035) than those treated
with vehicle. There were trends toward decreased gross abdominal score and decreased cecal collagen content. Procollagen I, procollagen III,
and IGF-I mRNAs also trended downward.
Conclusions: Resveratrol decreases inﬂammatory cytokines and TGF-b1 in the PG-PS model of Crohn’s disease and demonstrates a promising
trend in decreasing tissue ﬁbrosis. These ﬁndings may have therapeutic applications in inﬂammatory bowel disease.
(Inﬂamm Bowel Dis 2012;18:613–623)
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T he natural history of Crohn’s disease (CD) is character-ized by segmental, transmural bowel wall inﬂammation
that waxes and wanes over years and often progresses to ﬁ-
brosis, critical luminal narrowing, and obstruction. There
are currently no effective medical therapies for ﬁbrotic
strictures in CD, leaving surgery as the only treatment for
symptomatic strictures.
Resveratrol (3,40,5-trihydroxy-trans-stilbene) is a phy-
toalexin present in the skin of red grapes and in peanuts and
blueberries.1 Previous reports have demonstrated that resvera-
trol has antioxidant,2–4 antiaging,4,5 and cancer chemopreven-
tive properties.1,2,4,6–9 Relevant to CD, resveratrol also has
antiinﬂammatory and antiﬁbrotic effects.10–18 Multiple in
vivo animal studies have demonstrated the antiinﬂammatory
effects of resveratrol in several organ systems,10,11 including
animal models of gastrointestinal tract inﬂammation.12–18
Resveratrol has been shown to have an antiﬁbrotic
effect in animal models of cirrhosis,19–21 renal ﬁbrosis,22
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cardiac ﬁbrosis,23 and vasculopathy.24,25 With regard to the
gastrointestinal tract, resveratrol protected against stricture
formation following experimental caustic esophageal
burns.18 To our knowledge, the antiﬁbrotic effects of
resveratrol have not been studied in inﬂammatory bowel
disease (IBD) or models thereof.
We previously showed that resveratrol decreases pro-
liferation and collagen I synthesis by rat intestinal smooth
muscle cells in vitro.26 The aim of this study was to deter-
mine if resveratrol has antiinﬂammatory and antiﬁbrotic
effects in the peptidoglycan–polysaccharide (PG-PS) rat
model of CD, which exhibits chronic intestinal inﬂamma-
tion and prominent ﬁbrosis.27,28
MATERIALS AND METHODS
Animals
These studies were approved by the University Commit-
tee on Use and Care of Animals at the University of Michi-
gan. Speciﬁc pathogen-free (SPF) female Lewis rats, 8–10
weeks of age and weighing 150–165 g, were obtained from
Harlan Laboratories (Indianapolis, IN). The animals were
housed under SPF and temperature-controlled conditions, with
light/dark cycles of 12/12 hours and free access to water and
standard rodent chow.
PG-PS Enterocolitis Model
As previously described,27,28 anesthetized rats under-
went laparotomy. With aseptic technique, intramural injections
of PG-PS (15 lg rhamnose/g body weight; PG-PS 10S from
Lee Laboratories / Becton Dickinson, Bedford, MA) were
administered at seven sites along the surgically exposed intes-
tine (in ileal Peyer’s patches, terminal ileum, and cecum)
using 33G needles. Control rats were injected with human se-
rum albumin (HSA; 45 lg/g body weight; sterile solution in
normal saline) in the same manner. After the operation, the
animals were closely monitored, weighed three times per
week, and allowed free access to rodent chow and water. In
this model, PG-PS induces transient acute inﬂammation, fol-
lowed by a quiescent phase, then a spontaneously reactivating
chronic granulomatous phase which begins by day 14 and is
associated with chronic intestinal inﬂammation and prominent
ﬁbrosis.27–29
Study Design
In each experiment there were four groups of 4–6 rats/
group: HSA-injected, given vehicle; HSA-injected, given
resveratrol; PG-PS-injected, given vehicle; PG-PS-injected,
treated with resveratrol.
Resveratrol Administration
Resveratrol treatment by daily gavage was begun on
day 1 postinjection. Three separate experiments were con-
ducted: 20 mg/kg/d, 40 mg/kg/d, and 100 mg/kg/d resveratrol
dosing. Resveratrol (Cat. no. R5010, >99% purity by GC;
Sigma Chemical, St. Louis, MO) was dissolved in absolute
alcohol at a concentration of 50 mg/mL. This stock solution
was stored at 20C in the dark. Immediately prior to use the
required volume of resveratrol stock solution was mixed with
sufﬁcient 1% carboxymethyl cellulose (CMC) in water to give
a gavage volume of 0.4 mL (for 20 mg/kg or 40 mg/kg dose)
or 1.0 mL (for 100 mg/kg dose). The control rats received the
same volume of alcohol in 1% CMC.
Gross Abdominal Score
On day 28 postinjection the animals were euthanized.
The abdomen was opened and gross ﬁndings were scored in a
blinded manner. The ‘‘gross abdominal score’’ was calculated
as the sum of the values (on 0–4 scales) assigned to: 1) num-
ber of cecal nodules; 2) extent of cecal wall thickening based
on the degree of opacity of the bowel wall and the perceived
thickness on palpation; 3) severity of thickening and contrac-
tion of the cecal and terminal ileal mesentery; 4) severity of
adhesions; and 5) number of liver nodules. The maximum pos-
sible score representing the most severe lesions is 20.28
Histologic Assessment
At the time of dissection a 1  2 cm portion of the wall
of the cecum was resected. One half of this piece of tissue
was shaped into a Swiss roll and placed in 10% neutral buf-
fered formalin; the remaining half was frozen for RNA analy-
sis (see below). A 0.5-cm length of the cecal tip was collected
and placed in formalin. After 24 hours the tissue was removed
from formalin, embedded in parafﬁn, and sectioned. From
each tissue sample, one section was stained with hematoxylin
and eosin (H&E) and another with a modiﬁcation of Masson’s
original trichrome stain. This trichrome system stains collagen
blue, nuclei purple-brown, and cytoplasm pink. All slides
were scored by a gastrointestinal pathologist (A.C.R.) in a
blinded manner for inﬂammation and ﬁbrosis based on the
scoring system shown in Table 1. The inﬂammation score for
a given tissue section is the sum of the scores given to the
four regions or features assessed for inﬂammation (four col-
umns under ‘‘Inﬂammation’’). The ﬁbrosis score for a given
tissue section is the sum of the scores given to the four
regions assessed for ﬁbrosis (four columns under ‘‘Fibrosis’’).
Colorimetric Analysis of Digital Images of
Trichrome-stained Sections for Cecal Wall
Collagen Content
Colorimetric analysis was done as previously described
on the trichrome-stained sections of cecum.29 Brieﬂy, digital
images of the stained tissue sections were captured using a
Polaroid SprintScan 35 Plus (model CS-3600) and recorded in
tagged image ﬁle (TIF) format. Image analysis was performed
on Mac OS 10.5.6. The image white background was removed
using Adobe Photoshop CS3 v. 10.0.1 (San Jose, CA). Color
segmentation analysis was then performed with MatLab
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software (R2009a; MathWorks, Natick, MA). Colors were
then converted into HSV (hue, saturation, value) color
space.30,31 Each pixel was categorized by color classiﬁcation
to identify its likely tissue type. Collagen area was deﬁned as
the distinct blue color region and was distinguished from mus-
cle, blood, and inﬂammatory cells. The total length of each
tissue section was measured. In cases of curved tissue, multi-
segment measurements were performed along the axis of the
muscularis propria, without regard to plicae. All linear meas-
urements were performed by J.A. on the digital images, using
Osirix software. The collagen area of each tissue section was
then normalized to tissue section size by dividing the number
of pixels in the blue collagen area by the length of the section.
Prior studies demonstrated an excellent correlation between
the results of colorimetric analysis of digital images of tri-
chrome-stained sections for cecal wall collagen content and
measurement of collagen type I content by western
immunoblot.29
Messenger RNA Analysis
One half of the 1  2 cm portion of PG-PS- or HSA-
injected cecum, harvested at the time of dissection as
described above, was snap-frozen in liquid nitrogen and
placed at 80C for later RNA extraction. RNA was isolated
from pulverized frozen cecal tissue using the RNeasy Midi
Kit (Qiagen, Valencia, CA) according to the manufacturer’s
instructions. The RNA concentration was calculated from the
absorbance at 260 nm. A portion of the RNA was reverse-
transcribed into cDNA using the High Capacity cDNA
Reverse Trancription Kit (Applied Biosystems, Foster City,
CA) according to the manufacturer’s instructions. cDNAs
were used in quantitative real-time polymerase chain reactions
(PCR) for procollagen types I and III (using primers and
probes previously designed by our laboratory to span an
intron26) as well as insulin-like growth factor I (IGF-I), trans-
forming growth factor beta 1 (TGF-b1), tumor necrosis factor
alpha (TNF-a), interleukin-1 beta (IL-1b), and interleukin-6
(IL-6) (using commercially available TaqMan Gene Expres-
sion Assays from Applied Biosystems). Results were normal-
ized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
mRNA levels (measured using commercially available Taq-
Man Gene Expression Assay); then fold change was calculated
as fold of the mean vehicle-treated HSA-injected control
value. All reactions were done in triplicate wells.
Statistical Analysis
Experimental results were assessed for signiﬁcance
using one-tailed unpaired t-tests, and dose–response relation-
ships were determined by linear regression. P < 0.05 was con-
sidered signiﬁcant.
Ethical Considerations
Animal use complied with the Guide for the Care and
Use of Laboratory Animals (Institute of Laboratory Animal
Resources, Commission on Life Sciences, National Research
Council; National Academies Press, Washington, DC, 2010;
ISBN-10: 0-309-15400-6).
RESULTS
PG-PS-injected vs. HSA-injected Rats
When PG-PS-injected (vehicle-treated) or HSA-
injected (vehicle-treated) rats from all three experiments
were combined, the gross abdominal score was greater in
PG-PS-injected than in HSA-injected animals (Fig. 1A;
11.93 6 1.42 vs. 0.20 6 0.11, respectively; P <
0.00000001; n ¼ 15/group). Histologic scores for both
inﬂammation and ﬁbrosis on H&E and trichrome-stained
sections were greater in PG-PS-injected than in HSA-
injected animals in the two experiments for which this was
performed (40 and 100 mg/kg/d experiments; Fig. 1B;
inﬂammation score: open bars, 11.00 6 0.82 vs. 0 6 0,
respectively, P < 0.00000001; ﬁbrosis score: ﬁlled bars,
8.11 6 0.68 vs. 0.11 6 0.11, respectively, P <
0.00000001; n ¼ 9/group). The collagen content of cecal
tissue as measured by colorimetric analysis of digital
images of trichrome-stained sections and expressed relative
TABLE 1. Histologic Scoring: Inﬂammation and Fibrosis
Score
Inﬂammation Fibrosis
Mucosal
(Crypt
Abscesses) Submucosal Serosal
Granulomas
(no.) Submucosal Serosal
Muscularis
Mucosae
Muscularis
Externa
0 None None None 0 None None None None
1 Focal Focal Focal 1–2 Focal Focal Focal Focal
2 Multifocal Patchy Patchy 3–4 Patchy Patchy Patchy Patchy
3 Conﬂuent
patchy
Diffuse Diffuse 5–9 Diffuse Diffuse Diffuse Diffuse
4 Diffuse Diffuse
severe
Diffuse
severe
Many/
necrotizing
Diffuse
severe
Diffuse
severe
Diffuse
severe
Diffuse
severe
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to tissue length (as described in Materials and Methods)
was found to be greater in PG-PS-injected than in HSA-
injected animals from these same experiments (Fig. 1C;
206.17 6 76.85 vs. 60.91 6 7.44, respectively; P < 0.02;
n ¼ 9/group). Additionally, quantitative real-time PCR,
performed on cecal tissue from the 40 and 100 mg/kg/d
experiments, demonstrated increased expression of procol-
lagen types I and III mRNAs in PG-PS-injected as com-
pared to HSA-injected animals (Fig 1D; procollagen type I:
open bars, 8.35 6 1.91 vs. 1.00 6 0.05, respectively, P <
0.001; procollagen type III: ﬁlled bars, 6.44 6 1.32 vs.
1.00 6 0.03, respectively, P < 0.001; n ¼ 9/group).
Representative trichrome-stained sections of cecum
from HSA-injected (control; Fig. 2A,B) and PGPS-injected
animals (vehicle-treated; Fig. 2C–F) are shown in Figure 2.
Trichrome-stained sections from PG-PS-injected rats (vehi-
cle-treated) demonstrated expansion of the submucosa and
serosa with collagen (stained blue) that disrupts the muscu-
laris externa (Fig. 2C,F). There were granulomas, some of
which were necrotizing, in the submucosa (Fig. 2D). The
mucosa has a mixed inﬂammatory cell inﬁltrate and occa-
sional crypt abscesses (Fig. 2E and insert).
Effects of Resveratrol in the PG-PS Model of CD
Animal Weight
There was no difference in the mean weight of
resveratrol-treated and vehicle-treated PG-PS-injected rats
in any of the three experiments or when animals from all
experiments were considered collectively (195.9 6 3.1 g
vs. 195.6 6 2.9 g, respectively; day 28 postinjection; n ¼
16/group).
Gross Abdominal Score
Resveratrol had a dose-dependent effect on gross ab-
dominal score in PG-PS-injected animals (Fig. 3). At 20
mg/kg/d, resveratrol had no effect on gross abdominal
score (9.50 6 2.05 vs. 9.33 6 1.63, resveratrol- vs. vehi-
cle-treated, respectively), and therefore no further analyses
were performed on tissues from this experiment. There was
a trend toward decreased gross abdominal score with 40
mg/kg/d resveratrol (8.67 6 1.52 vs. 10.00 6 2.41, resver-
atrol- vs. vehicle-treated, respectively; P ¼ 0.32), and this
trend was more prominent with the 100 mg/kg/d dose
(13.80 6 2.29 vs. 18.25 6 0.85, resveratrol- vs. vehicle-
treated, respectively; P ¼ 0.07). The mean percent decrease
in gross abdominal score for the three resveratrol doses
was 1.8%, 13.3%, and 24.4% for 20, 40, and 100 mg/kg/
d, respectively (Fig. 3B), demonstrating a trend that was
not statistically signiﬁcant.
Histologic Scoring of Inflammation and Fibrosis
H&E and trichrome-stained sections were examined
in a blinded manner and scored for inﬂammation and ﬁbro-
sis. There was no signiﬁcant difference in inﬂammation
score between resveratrol- and vehicle-treated PG-PS-
injected animals with either 40 or 100 mg/kg/d dosing
(10.8 6 1.4 vs. 9.8 6 1.0 and 10.6 6 1.8 vs. 12.5 6 1.0
[P ¼ 0.21], respectively; Fig. 4A). A decrease in ﬁbrosis
score was seen with 100 mg/kg/d dosing (6.4 6 1.1 vs. 9.8
6 1.0, resveratrol- vs. vehicle-treated PG-PS-injected ani-
mals, respectively; P ¼ 0.035; Fig. 4B). Representative tri-
chrome-stained sections of cecum from PG-PS-injected rats
treated with resveratrol (100 mg/kg/d) are shown in Figure
2G,H. Expansion of the submucosa and disruption of the
muscularis externa by bands of collagen was less marked
in the resveratrol-treated rats.
FIGURE 1. By all measurements used, vehicle-treated PG-PS-
injected rats developed more ﬁbrosis at day 28 postinjection than
did vehicle-treated HSA-injected rats. All results shown are means;
error bars reﬂect SEM. (A) PG-PS-injected animals had greater gross
abdominal scores (P < 0.001), which are the sums of the scores for
adhesions, cecal wall thickening, mesenteric thickening and con-
traction, cecal nodules, and liver nodules, each graded on a scale
of 0–4, with a maximum possible score of 20 (n ¼ 15/group; com-
bined data from all three experiments). (B) PG-PS-injected animals
had greater histologic inﬂammation and ﬁbrosis scores when H&E
and trichrome-stained sections of cecum were examined in a
blinded manner and scored for the amounts of inﬂammation and
ﬁbrosis as described in Materials and Methods (inﬂammation score,
open bars; ﬁbrosis score, ﬁlled bars; maximum possible score for
each is 16; P < 0.00000001 for both; n ¼ 9/group; combined data
from the 40 and 100 mg/kg/d experiments). (C) The collagen con-
tent of cecal tissue, as analyzed by colorimetric analysis of digital
images of trichrome-stained sections, was also greater in PG-PS-
injected than in HSA-injected animals (P < 0.02). Collagen is
stained blue in the trichrome system used; thus, blue pixels reﬂect
collagen. Variation in the sizes of the pieces of tissue analyzed was
controlled for by normalizing to tissue length. (n ¼ 9/group; com-
bined data from the 40 and 100 mg/kg/d experiments) (D) Cecal
tissue of PG-PS-injected rats had increased procollagen type I
(open bars; P < 0.001) and procollagen type III (ﬁlled bars; P <
0.001) mRNA expression as measured by quantitative real-time
PCR; the results were normalized to GAPDH and expressed as fold
the mean HSA-injected control value (n ¼ 9/group; combined data
from the 40 and 100 mg/kg/d experiments).
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FIGURE 2. Microscopic appearance of representative trichrome-stained sections of cecum from HSA-injected control rats (A,B), PG-PS-
injected rats (vehicle-treated; C–F), and PG-PS-injected rats treated with resveratrol 100/mg/kg/d (G,H). A,C,G are 40 original magniﬁcation
photomicrographs of cecum from HSA-injected control rats, PG-PS-injected rats (vehicle-treated), and PG-PS-injected rats treated with
resveratrol, respectively. B,D–F,H are 100 original magniﬁcation photomicrographs of cecum from HSA-injected control rats, PG-PS-injected
rats (vehicle-treated), and PG-PS-injected rats treated with resveratrol, respectively. PG-PS-injected (vehicle-treated) rats have dense collagen
(stained blue) expanding the submucosa and disrupting the muscularis externa (muscularis externa in brackets in C,F; disruption indicated
by an arrow). Mucosal inﬂammation is shown in brackets in E; the insert is 200 original magniﬁcation of a crypt abscess. PG-PS-injected
(vehicle-treated) rats have granulomas in the submucosa, many of which are necrotizing (asterisk in D). PG-PS-injected rats treated with
resveratrol 100/mg/kg/d (G,H) have less collagen in the submucosa and serosa, and the integrity of the muscularis externa is generally
maintained compared with that of the PG-PS-injected (vehicle-treated) rats. The brackets in H indicate foamy histiocytes in the submucosa
in the PG-PS-injected rats treated with resveratrol. [Color ﬁgure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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Colorimetric Analysis of Digital Images of
Trichrome-stained Sections for Cecal Wall
Collagen Content
Trichrome-stained sections of cecum were analyzed
for collagen content as described in Materials and Methods.
At the 100 mg/kg/d resveratrol dose, there was a trend to-
ward decreased cecal collagen content with resveratrol
treatment (Fig. 5; 142.19 6 20.63 vs. 206.17 6 76.85,
resveratrol- vs. vehicle-treated PG-PS-injected animals,
respectively; P ¼ 0.16).
Proinflammatory Cytokines
Using cDNA reverse transcribed from cecal RNA,
quantitative real-time PCR was performed to measure
expression of mRNAs of representative proinﬂammatory
cytokines that are typically increased in inﬂamed tissue. At
the 40 mg/kg/d resveratrol dose (Fig. 6, gray bars) there
was a trend toward decreased IL-1b and IL-6 mRNA
expression in resveratrol-treated vs. vehicle-treated PG-PS-
injected animals (IL-1b: 4.78 6 0.93 vs. 8.13 6 3.00,
respectively, P ¼ 0.14; IL-6: 12.55 6 4.52 vs. 22.02 6
8.05, respectively, P ¼ 0.16), but no effect of resveratrol
on TNF-a mRNA expression. At the 100 mg/kg/d
FIGURE 3. Effect of resveratrol on ﬁbrosis as assessed by gross ab-
dominal score. Resveratrol (20, 40, or 100 mg/kg/d) or vehicle was
given by daily gavage on days 1–27 postinjection to PG-PS- and
HSA-injected rats. The animals were euthanized on day 28. (A)
Gross abdominal scores were calculated (the sum of the scores
[each on 0–4 scales] for adhesions, mesenteric thickening and con-
traction, cecal wall thickening, cecal nodules, and liver nodules;
maximum possible score is 20). (Results shown are means; n ¼ 4–
6/group; error bars reﬂect SEM.) (B) Results are shown as the mean
percent decrease in gross abdominal score in PG-PS-injected ani-
mals that were treated with resveratrol relative to PG-PS-injected
animals given vehicle.
FIGURE 4. Effect of resveratrol on inﬂammation and ﬁbrosis as
assessed on histologic examination. H&E and trichrome-stained sec-
tions were examined in blinded fashion and scored for inﬂamma-
tion (A) and for ﬁbrosis (B) using a system outlined in Materials
and Methods (Table 1). (Results shown are means; n ¼ 4–6/group;
error bars reﬂect SEM.)
FIGURE 5. Effect of resveratrol on ﬁbrosis using colorimetric analysis
of digital images of trichrome-stained sections of cecum to measure
collagen content. Digital images of trichrome-stained tissue sections
were captured; color segmentation analysis was performed to count
the number of blue pixels in each tissue section. The number of
blue pixels was normalized to tissue section length to account for
differences in the sizes of the pieces of tissue analyzed. (Results
shown are means; n ¼ 4–5/group; error bars reﬂect SEM.)
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resveratrol dose (Fig. 6, black bars) the expression of the
mRNAs of all three inﬂammatory cytokines was decreased
(IL-1b: 3.50 6 1.08 vs. 10.79 6 1.88, P ¼ 0.005; IL-6:
17.11 6 9.22 vs. 45.64 6 8.83, P ¼ 0.03; TNF-a: 0.80 6
0.14 vs. 1.89 6 0.22, P ¼ 0.002; resveratrol-treated vs. ve-
hicle-treated PG-PS-injected animals, respectively).
Profibrotic Factors
There was a trend toward decreased IGF-I mRNA
expression (2.45 6 0.50 vs. 3.10 6 0.70, P ¼ 0.23; resver-
atrol-treated vs. vehicle-treated PG-PS-injected animals,
respectively) with 40 mg/kg/d resveratrol treatment (Fig. 7,
gray bars). There was no effect on TGF-b1, procollagen
type I, or procollagen type III mRNA levels at the 40 mg/
kg/d resveratrol dose. However, with the 100 mg/kg/d dose
(Fig. 7, black bars) TGF-b1 mRNA expression was
decreased (2.24 6 0.37 vs. 4.06 6 0.58, resveratrol-treated
vs. vehicle-treated PG-PS-injected animals, respectively; P
¼ 0.01) and the other proﬁbrotic factors that were meas-
ured showed a trend toward decreased expression (procolla-
gen type I: 6.58 6 2.59 vs. 12.47 6 2.96, P ¼ 0.09; pro-
collagen type III: 5.45 6 2.37 vs. 9.03 6 2.08, P ¼ 0.16;
IGF-I: 4.01 6 1.11 vs. 6.51 6 2.44, P ¼ 0.17; resveratrol-
treated vs. vehicle-treated PG-PS-injected animals,
respectively).
DISCUSSION
CD is a chronic relapsing inﬂammatory disease that
involves primarily the distal small bowel and colon but can
affect any part of the gastrointestinal tract. The characteris-
tic transmural inﬂammatory state triggers smooth muscle
hyperplasia and abnormal deposition of collagen and other
extracellular matrix components resulting in ﬁbrosis and
luminal narrowing.32 Potent immunomodulators and bio-
logic therapies are the mainstay of therapy for CD. These
therapies are highly effective in treating inﬂammation in
most patients; however, the cost of the drugs and potential
toxicities including life-threatening infections and cancer
are concerning to both physicians and patients. Further,
their effects on ﬁbrosis and their ability to alter the natural
history of the disease are not known. Indeed, there are no
IBD therapies that have been speciﬁcally shown to
decrease ﬁbrosis. We investigated the ability of resveratrol,
a naturally occurring phytochemical, to decrease inﬂamma-
tion and ﬁbrosis in an animal model of CD. We found that
resveratrol decreases inﬂammatory cytokines and proﬁ-
brotic factors and decreases procollagen mRNAs,
supporting a potential therapeutic beneﬁt. The effects on
inﬂammation and ﬁbrosis in this model are modest, with
some parameters demonstrating signiﬁcance and others
showing a trend, suggesting that resveratrol may be effec-
tive as an adjunct to current therapies rather than a primary
therapeutic agent. Our data are consistent with a role for
resveratrol as an effective, safe, economical, and ‘‘natural’’
adjunct to current therapies for CD.
Previous animal studies have demonstrated that
resveratrol has antiinﬂammatory effects in several organ
systems,10,11 including the gastrointestinal tract.12–18 The
antioxidant and antiinﬂammatory actions of resveratrol
FIGURE 6. Effect of resveratrol on proinﬂammatory cytokines.
Quantitative real-time PCR was used to measure IL-1b, IL-6, and
TNF-a mRNA expression in cecal tissue. The values for each speci-
men were normalized to the GAPDH mRNA level of that specimen.
Results are shown relative to the mean for vehicle-treated HSA-
injected animals. Statistical signiﬁcance was achieved for all of
these cytokines at the 100 mg/kg/d dose. (Results shown are
means; n ¼ 4–6/group; error bars reﬂect SEM.)
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occur via its inhibition of prostaglandin production, cyclo-
oxygenase-2 activity, and nuclear factor-jB (NF-jB) activ-
ity.33 Resveratrol has also been shown to have antiﬁbrotic
effects in animal models of disease and injury involving
the esophagus, liver, kidney, lung, heart, and vascula-
ture,19–25,34 which is attributed in part to TGF-b inhibition
and reduction of oxidative stress19,20; the antiﬁbrotic poten-
tial of resveratrol in animal models of IBD has not been
previously assessed. The ﬁnding that resveratrol protected
against stricture formation in an animal study of caustic
esophageal burns18 suggests that resveratrol might protect
against strictures elsewhere in the gastrointestinal tract,
such as the intestinal strictures that frequently occur in CD.
Resveratrol decreases inﬂammation in the DSS (dex-
tran sulfate sodium)12–16 and TNBS (2,4,6-trinitrobenzene-
sulfonic acid)17 rodent models of IBD. Both are better
models of ulcerative colitis than CD because involvement
in these models is restricted to the colon, and neither has
signiﬁcant ﬁbrosis as performed using most experimental
protocols. The PG-PS model more closely resembles CD
with involvement in the terminal ileum and right colon,
histologic features including granulomatous inﬂammation
and prominent ﬁbrosis, and extraintestinal manifestations
such as arthritis that are commonly observed in CD
patients. Further, the inﬂammation in this model is T-cell-
mediated and has a similar inﬂammatory cytokine pro-
ﬁle.27,28,35 Mechanistically, muramyl dipeptide, the sub-
strate for the CD susceptibility gene product NOD2,36 is a
moiety within the PG-PS macromolecule. Consistent with
prior literature, the presence of inﬂammation and ﬁbrosis,
as well as involvement of the terminal ileum and colon,
make this model relevant to CD. Consistency and high pen-
etrance of this model made it a good choice for drug test-
ing. Based on the reports in the literature of resveratrol’s
antiinﬂammatory and antiﬁbrotic properties, and the
encouraging results of our in vitro experiments in which
resveratrol-treated rat intestinal smooth muscle cells
showed a decrease in collagen type I synthesis,26 we pro-
ceeded with the in vivo studies presented here.
A review of the literature6–9,12–25 indicated that a
wide range of resveratrol doses had been used in in vivo
rodent studies; physiologic and biochemical effects of
resveratrol have been observed with doses between 0.2 and
100 mg/kg/d. With regard to toxicity, it has been shown
that a resveratrol dose of 300 mg/kg/d for 28 days in rats
had no adverse effects.37,38 A dosage range of 20–100 mg/
kg/d was chosen for our studies in the PG-PS model. There
was a dose-dependent decrease in gross abdominal score
(Fig. 3). At the 100 mg/kg/d dose there was a signiﬁcant
reduction in proinﬂammatory cytokine mRNAs (Fig. 6).
FIGURE 7. Effect of resveratrol on proﬁbrotic factors. Quantitative real-time PCR was used to measure procollagen type I, procollagen type
III, IGF-I, and TGF-b1 mRNA expression in cecal tissue. The values for each specimen were normalized to the GAPDH mRNA level of that
specimen. Results are shown relative to the mean for vehicle-treated HSA-injected animals. (Results shown are means; n ¼ 4–6/group; error
bars reﬂect SEM.)
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This observation is in agreement with work by others using
other models of IBD in rats: Larrosa et al12 in the DSS
model and Martı´n et al17 in the TNBS model found that
resveratrol reduced the intestinal inﬂammatory response to
those inducing agents. Similar antiinﬂammatory effects of
resveratrol have been reported when the DSS model is car-
ried out in mice.13–16 Singh et al15 found that 100 mg/kg
resveratrol administered every other day by gavage, with-
out a pretreatment period, was required for protection of
mice from DSS colitis. Our ﬁnding of signiﬁcant reductions
in the levels of inﬂammatory cytokine mRNAs (Fig. 6) but
only a trend toward a decrease in the histologic inﬂamma-
tion score (Fig. 4A) may reﬂect factors including differen-
ces in the sensitivities of the assessment tools or, perhaps,
an early decrease in the level of activation of the inﬂamma-
tory cells that would be reﬂected in decreased tissue
inﬂammation at a later timepoint.
Resveratrol at a dose of 100 mg/kg/d decreased tissue
ﬁbrosis in the PG-PS model. Reduction in ﬁbrosis was seen
on histologic examination (Fig. 4B) and was supported by
reduced TGF-b1 mRNA levels (Fig. 7) and by trends to-
ward lower gross abdominal score (Fig. 3), lower cecal
wall collagen content on colorimetric analysis of digital
images of trichrome-stained sections (Fig. 5), and
decreased procollagen type I, procollagen type III, and
IGF-I mRNA levels (Fig. 7). The ﬁnding of decreased ﬁ-
brosis with resveratrol treatment is consistent with previous
reports of antiﬁbrotic effects of resveratrol in a variety of
in vivo models of disease.18–25,34 The decrease in TGF-b1
mRNA in our study is in agreement with previous studies
that have demonstrated a decrease in the level of this proﬁ-
brotic factor with resveratrol treatment, and is consistent
with the proposed mechanism of resveratrol’s antiﬁbrotic
action.19,20,21 TGF-b1 is a potent proﬁbrotic factor that
plays a role in the pathogenesis of CD strictures.32
There was a trend toward a decrease in IGF-I mRNA
with resveratrol treatment in our study. IGF-I has potent
proﬁbrotic effects and data suggest that it plays a role in
the pathogenesis of strictures in CD.39,40 The IGF-I system
also plays a role in the development of cancer, particularly
colon cancer.41,42 While we did not directly assess chemo-
prevention in our study, resveratrol’s chemopreventive
effects have been reported in a number of in vitro and in
vivo models.2,3,6–9,13,33 Relevant to IBD, these reports
include chemopreventive effects in colon.7,8,13 A recent
study in humans, comparing pre- and postintervention tis-
sue, demonstrated decreased tumor cell proliferation in tis-
sue from colorectal cancer patients given resveratrol for the
8 days prior to surgical resection of their tumor.43 It was
also recently shown that serum IGF-I levels decreased in
volunteers taking resveratrol.44 The effect of resveratrol on
IGF-I is especially relevant to CD since IGF-I has been
implicated in intestinal ﬁbrosis in this disease39,40 and since
patients with colonic CD have an increased risk of colon
cancer.45
Relevant to treatment of CD, enterohepatic circula-
tion of resveratrol has been demonstrated experimentally,46
increasing exposure of the gut to resveratrol. However,
human and rat pharmacokinetic studies have shown that
resveratrol is rapidly and extensively metabolized and has
low bioavailability.44,47,48 In humans, achievable blood lev-
els of unconjugated resveratrol are in the range of 0.02–0.5
lM when doses of 0.6–5.0 g/d are given.5,44,48,49 Circulat-
ing levels of its major metabolites (resveratrol-3-O-sulfate,
resveratrol-40-O-glucuronide, and resveratrol-3-O-glucuro-
nide) have been found to be much higher than levels of the
parent compound.44 Despite emerging evidence that at least
some resveratrol metabolites may be pharmacologically
active,4,44,50,51 recent studies suggest that resveratrol doses
of 0.5–2.5 g/d may be required for chemopreventive efﬁ-
cacy in human colon.43,44 Doses of 2.5 and 5.0 g once
daily were safe, but caused mild to moderate gastrointesti-
nal symptoms.44 While administration as divided doses
might decrease the occurrence of side effects, other
approaches may be useful to allow lower resveratrol doses
to be pharmacologically effective. It has been reported that
ﬂavonoids such as quercitin inhibit the conjugation of
resveratrol and thereby increase resveratrol bioavailabil-
ity,52 suggesting that dietary manipulations could perhaps
allow therapeutic blood and tissue levels of resveratrol to
be more readily achieved. Increasing the aqueous solubility
of resveratrol was found to increase the rate of absorption
but not the bioavailability of orally administered resvera-
trol.53 More recently, the development of resveratrol pro-
prodrugs was found to improve the efﬁcacy of resveratrol
in preventing the development of DSS-induced colitis in
mice.54
Although it has been reported that resveratrol modu-
lates the expression of some cytochrome P450 and other
drug metabolizing enzymes4,5 and could therefore affect
pharmacokinetics of certain drugs, resveratrol is generally
safe with minimal side effects.44,48 The human equivalent
dose55 of a 100 mg/kg/d dose in rats is 16 mg/kg/d, or 1.12
g/d for a 70-kg individual. Thus, based on available litera-
ture and our rodent study, it is not unreasonable to con-
clude that concentrations of resveratrol needed to decrease
ﬁbrosis in CD can be attained in the blood or target tissue
in humans. However, deﬁnitive studies will need to be per-
formed in CD patients.
In conclusion, we found that resveratrol decreased
cecal wall ﬁbrosis as assessed histologically and this was
associated with a decrease in the proﬁbrotic cytokine TGF-
b1 as well as a number of inﬂammatory cytokines (IL-1b,
IL-6, and TNF-a) in the PG-PS rat model of CD. Promis-
ing trends toward decreased expression of other proﬁbrotic
factors (IGF-I, procollagen type I, and procollagen type III
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mRNAs), decreased gross abdominal score, decreased cecal
wall collagen content, and decreased histologic inﬂamma-
tion score were also demonstrated. These results, together
with resveratrol’s reported chemopreventive effects, sug-
gest that resveratrol may be a valuable adjunct to our
standard immunomodulator therapies for CD. Translational
studies investigating the effect of this compound in CD
patients would be the next step.
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